To target the untargetable: elucidation of synergy of APR-246 and azacitidine in

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 34 citations in OpenAlex.

1. Decitabine plus all-Haematologica · 2026
   Trial
2. LFPM inhibition of RING1-mediated p53Cell death and differentiation · 2026
   Article
3. p53: from understanding its structure to advances in therapeutic targeting.Signal transduction and targeted therapy · 2026
   Review
4. Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatments.Journal of internal medicine · 2025
   Review
5. Impact of p53-associated acute myeloid leukemia hallmarks on metabolism and the immune environment.Frontiers in pharmacology · 2024
   Review
6. PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma.Frontiers in molecular biosciences · 2023
   Article
7. Molecular-Targeted Therapy for Tumor-Agnostic Mutations in Acute Myeloid Leukemia.Biomedicines · 2022
   Review
8. Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.The Journal of clinical investigation · 2022
   Article
9. Wild type and gain of function mutant TP53 can regulate the sensitivity of pancreatic cancer cells to chemotherapeutic drugs, EGFR/Ras/Raf/MEK, and PI3K/mTORC1/GSK-3 pathway inhibitors, nutraceuticals and alter metabolic properties.Aging · 2022
   Article
10. Whom should we treat with novel agents? Specific indications for specific and challenging populations.Hematology. American Society of Hematology. Education Program · 2021
    Article
11. The beginning of a new therapeutic era in acute myeloid leukemia.EJHaem · 2021
    Review
12. Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia?Cancers · 2021
    Review
13. Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting.Biochimica et biophysica acta. Reviews on cancer · 2021
    Review
14. Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine.Cancers · 2021
    Review
15. Antitumor Effects of PRIMA-1 and PRIMA-1Cells · 2021
    Review
16. The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing.Cancers · 2020
    Review

Corrections and comments

• Comment on
  Synergistic effects of PRIMA-12020

Authors and funding

1 author at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as